Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

The purpose of the study is to provide comprehensive follow-up in patients with Long QT Syndrome (LQTS) and gain additional information regarding genotype-phenotype correlation and effective management and treatment options.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Long QT Syndrome Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Heart Defects, Congenital Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

Up to 20 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Cardiology Associates

Austin, Texas, 78756, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children and/or young adults diagnosed with heterogeneous repolarization disorder who have genotype positive Long QT, or
Newly diagnosed mutation positive patients with a confirmed test

Exclusion criteria

Children who are phenotypically positive with no molecular testing
Children that are phenotypically positive but genotype negative

Treatment and study plan

Primary outcomes

Adverse Cardiac Events on patients with genotype positive LQT1 who have a normal EKG and absence of symptoms, but a molecular confirmation of LQT1.

Time frame: Enrollment is expected to take approximately 5 years. The patients will be followed until they are no longer cared for by a pediatric cardiology facility (typically post-college) or approximately 21 years of age.

Secondary outcomes

Adverse Cardiac Events on patients with both phenotype and genotype positive.

Time frame: Enrollment is expected to take approximately 5 years. The patients will be followed until they are no longer cared for by a pediatric cardiology facility (typically post-college) or approximately 21 years of age.

Sponsors and collaborators

Lead sponsor

Pediatrix

Other

Registry information

Important dates

Study start: 2012
Primary completion: 2018
Study completion: 2018
First posted: Oct 12, 2012
Registry last updated: May 6, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed